Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients

Medical Science Monitor

Volumn 14, Issue 10, 2008, Pages

  Özkök, Elif ^a   Aydin, Makbule ^a   Babalik, Erhan ^a   Ozbek, Zeynep ^b   Ince, Nurhan ^c   Kara, Ihsan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Eyup State Hospital   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Coronary artery disease; Matrix metalloproteinase 3; Paraoxonase 1; Restriction fragment length polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; STROMELYSIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

ADULT; AGED; ALLELES; ARYLDIALKYLPHOSPHATASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TURKEY;

EID: 54249131332     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Loyd-Jones DM, Larson MG, Beiser A, Levy D: Lifetime risk developing artery coronary disease. Lancet, 1999; 353: 89-92
2. Kuremoto K, Watanabe Y, Ohmura H et al: R/R genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects. J Atheroscler Thromb, 2003; 10: 85-92
3. Huang Y, Mironova M, Lopes-Virella MF: Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol, 1999; 19: 2640-47
4. Navab M, Berliner JA, Watson AD et al: The yin and yang of oxidation in the development of fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol, 1996; 16: 831-42
5. Navab M, Hama SY, Anantharamaiah GM et al: Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res, 2000; 41: 1495-508
6. Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis, 1995; 115: 243-53
7. Watson AD, Berliner JA, Hama SY et al: Protective effect of high density lipoprotein associated paraoxonase: inhibition of biological activity of minimally oxidized low density lipoprotein. J Clin Invest, 1995; 96: 2882-91
8. Blatter MC, James RW, Messmer S et al: Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem, 1993; 211: 871-79
9. Kelso GJ, Stuart WD, Richter RJ et al: Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry, 1994; 33: 832-39
10. Humbert R, Adler DA, Disteche CM et al: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet, 1993; 3: 73-76
11. Adkins S, Gan KN, Mody M, La du DN: Molecular basis for the polymorphic form of human serum paraoxoanase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet, 1993; 52: 598-608
12. Rajagopalan S, Meng XP, Ramasamy S et al: Reactive oxygen species produced by macrophage-derived foam cells regulates the activity of vascular matrix metalloproteinases in vitro. J Clin Invest, 1996; 98: 2572-79
13. Orbe J, Fernandez L, Rodriguez JA et al: Different expression of MMPs/TIMP-1 in human atherosclerotic lesions.Relation to plaque features and vascular bed. Atherosclerosis, 2003; 170: 269-76
14. Gottschall PE, Deb S. Regulation of matrix metalloproteinase expressions in astrocytes. Neuroimmunomodulation, 1996; 3: 69-75
15. Newby AC, Johnson JL: Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. Circ Res, 2005; 97: 958-60
16. Ghilardi G, Biondi ML, Caputo M et al: A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res, 2002; 8: 3820-23
17. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 1988; 16: 1215
18. Quinones S, Saus J, Otani Y et al: Transcriptional regulation of human stromelysin. J Biol Chem, 1989; 264; 8339-44
19. Hoh J, Ott J: Mathematical multi-locus approaches to localizing complex human trait genes. Nat Rev Genet, 2003; 4: 701-9
20. Mackness MI, Mackness B, Durrington PN et al: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol, 1996; 7: 69-76
21. Ichihara S, Noda A, Nagata K et al: Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovascular Research, 2006; 69: 726-35
22. Jarvik GP, Rozek LS, Brophy VH et al: Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1 (55) genotype. Arterioscler Thromb Vasc Biol, 2000; 20: 2441-47
23. Aviram M, Furman B: LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs antioxidants.Mol Cell Biochem, 1998; 188: 149-59
24. Mackness MI, Arrol S, Mackness B, Durrington PN: Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet, 1997; 349: 851-52
25. Aviram M, Billecke S, Sorenson R et al: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Tromb Vasc Biol, 1998; 18: 1617-24
26. Stocker R, Keaney JF: Role of oxidative modifications in atherosclerosis. Physiol Rev, 2004; 84: 1381-78
27. Shah PK, Falk E, Badimon JJ et al: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation, 1995; 92: 1565-69
28. Silence J, Lupu F, Collen D, Lijnen HR: Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Atheroscler Thromb Vasc Biol, 2001; 21: 1440-45
29. Ye S, Eriksson P, Hamsten A et al: Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem, 1996; 271: 13055-60
30. Abedin M, Tintut Y, Demer LL: Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol, 2001; 21: 1440-45
31. Pollanen PJ, Lehtimaki T, Ilveskoski E et al: Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase-3. The Helsinki Sudden Death Study. Atherosclerosis, 2002; 164: 329-35
32. Aynacioglu AS, Kepekci Y: The human paraoxonase Gln -Arg192 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int J Cardiol, 2000; 12: 33-37
33. Beaudeux JL, Giral P, Bruckert E et al: Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis, 2003; 169: 139-46
34. Rouis M, Nigon F, Lafuma C et al: Expression of elastase activity by human monocyte-macrophages is modulated by cellular cholesterol content, inflammatory mediators, and phorbol myristate acetate.Arteriosclerosis, 1990; 10: 246-55
35. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circulation Res, 2000; 87: 840-49